ProKidney Corp. (PROK), a clinical-stage company specializing in cell therapies for chronic kidney disease (CKD), reported a narrowed net loss for 2025, decreasing to $82.63 million from $102.15 million the previous year. Despite a decline in cash reserves to $270 million, the company anticipates sufficient funding for operations through mid-2027 as it advances its lead candidate, Rilparencel, currently in Phase 3 trials.
The significance of ProKidney’s developments is underscored by the growing CKD patient population in the U.S., estimated at over one million. The company is on track to complete patient enrollment for its Phase 3 studies by mid-2026, with plans for a Biologics License Application (BLA) submission by late 2027. These milestones could position Rilparencel as a critical therapeutic option for patients facing advanced CKD and type 2 diabetes.
For those following biotech trends, ProKidney’s progress and the potential market impact of Rilparencel are worth a closer look. I recommend checking out the full article for more insights into their financials and clinical timelines.
Source: nasdaq.com